XTL Announces Delisting From the Official List of the United Kingdom Listing Authority Processing Fees on Transfer of Ordinary Shares Into ADRs to be Waived for

an Additional Month



    VALLEY COTTAGE, New York, October 31 /PRNewswire-FirstCall/ -- XTL
 Biopharmaceuticals Ltd. (NASDAQ:   XTLB; TASE: XTL) today announced that the
 Company's ordinary shares have been delisted from the Official List of the
 United Kingdom Listing Authority, pursuant to the October 2, 2007 vote at
 the Company's Extraordinary General Meeting. With the cancellation of the
 listing on the London Stock Exchange, shareholders may deposit their
 ordinary shares with the Company's depositary bank, The Bank of New York,
 in exchange for American Depositary Receipts, or ADRs, which are traded on
 NASDAQ, or trade their ordinary shares on the TASE.
     XTL Biopharmaceuticals Ltd. has further announced that issuances of
 ADRs by The Bank of New York will be processed free of the customary
 charges of The Bank of New York for an additional month, through November
 30, 2007. The Bank of New York will issue ADRs representing American
 Depositary Shares, or ADSs, if shareholders or their broker deposit
 Ordinary Shares with The Bank of New York's Custodian, either the Tel Aviv
 office of Bank Hapoalim B.M., or the London office of The Bank of New York.
 One ADR will represent an ownership interest in ten of the Company's
 Ordinary Shares.
     Interested investors should contact their brokers to discuss the waived
 fee and, should they have any questions, can contact The Bank of New York
 in either London or New York as follows:
     London:
     Mark Lewis,
     Vice President,
     Tel +44(0)20-7964-6089,
     Fax +44(0)20-7964-6024,
     marlewis@bankofny.com
 
     New York:
     Jason Paltrowitz,
     Vice President,
     Tel +1-212-815-2077,
     Fax +1-212-815-3004,
     jpaltrowitz@bankofny.com
     About XTL Biopharmaceuticals Ltd.
     XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the development of
 therapeutics for the treatment of neuropathic pain and hepatitis C. XTL is
 developing Bicifadine, a serotonin and norepinephrine reuptake inhibitor,
 for the treatment of diabetic neuropathic pain. XTL is also developing
 several novel pre-clinical hepatitis C small molecule inhibitors. XTL also
 has an active in-licensing and acquisition program designed to identify and
 acquire additional drug candidates. XTL is publicly traded on the NASDAQ
 and Tel-Aviv Stock Exchanges (NASDAQ:   XTLB; TASE: XTL).
     Cautionary Statement
     Some of the statements included in this press release, particularly
 those anticipating continued undisrupted trading of the Company's ADRs on
 NASDAQ and similar matters, may be forward-looking statements that involve
 a number of risks and uncertainties. For those statements, we claim the
 protection of the safe harbor for forward-looking statements contained in
 the Private Securities Litigation Reform Act of 1995. Risk factors that
 could adversely affect our operations are identified from time to time in
 our reports filed with the Securities and Exchange Commission, including
 our annual report on Form 20-F filed with the Securities and Exchange
 Commission on March 23, 2007. Any forward-looking statements set forth in
 this press release speak only as of the date of this press release. We do
 not intend to update any of these forward-looking statements to reflect
 events or circumstances that occur after the date hereof. This press
 release and prior releases are available at http://www.xtlbio.com. The
 information in our website is not incorporated by reference into this press
 release and is included as an inactive textual reference only. This press
 release is for informational purposes only and is not an offer to by or the
 solicitation of an offer to sell any securities.
     Contact:
 
     Ron Bentsur,
     Chief Executive Officer
     Tel: +1-845-267-0707 ext. 225
 
 

SOURCE XTL Biopharmaceuticals Ltd

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.